177 related articles for article (PubMed ID: 27213581)
21. S100A16 promotes cell proliferation and metastasis via AKT and ERK cell signaling pathways in human prostate cancer.
Zhu W; Xue Y; Liang C; Zhang R; Zhang Z; Li H; Su D; Liang X; Zhang Y; Huang Q; Liu M; Li L; Li D; Zhao AZ; Liu Y
Tumour Biol; 2016 Sep; 37(9):12241-12250. PubMed ID: 27240591
[TBL] [Abstract][Full Text] [Related]
22. The olfactory receptor OR51E2 activates ERK1/2 through the Golgi-localized Gβγ-PI3Kγ-ARF1 pathway in prostate cancer cells.
Xu X; Khater M; Wu G
Front Pharmacol; 2022; 13():1009380. PubMed ID: 36313302
[TBL] [Abstract][Full Text] [Related]
23. ADP-ribosylation factor 1 controls the activation of the phosphatidylinositol 3-kinase pathway to regulate epidermal growth factor-dependent growth and migration of breast cancer cells.
Boulay PL; Cotton M; Melançon P; Claing A
J Biol Chem; 2008 Dec; 283(52):36425-34. PubMed ID: 18990689
[TBL] [Abstract][Full Text] [Related]
24. Suppression of breast cancer metastasis through the inactivation of ADP-ribosylation factor 1.
Xie X; Tang SC; Cai Y; Pi W; Deng L; Wu G; Chavanieu A; Teng Y
Oncotarget; 2016 Sep; 7(36):58111-58120. PubMed ID: 27517156
[TBL] [Abstract][Full Text] [Related]
25. Functional disruption of the Golgi apparatus protein ARF1 sensitizes MDA-MB-231 breast cancer cells to the antitumor drugs Actinomycin D and Vinblastine through ERK and AKT signaling.
Luchsinger C; Aguilar M; Burgos PV; Ehrenfeld P; Mardones GA
PLoS One; 2018; 13(4):e0195401. PubMed ID: 29614107
[TBL] [Abstract][Full Text] [Related]
26. ADP-ribosylation factor 1 (ARF1) takes part in cell proliferation and cell adhesion-mediated drug resistance (CAM-DR).
Xu X; Wang Q; He Y; Ding L; Zhong F; Ou Y; Shen Y; Liu H; He S
Ann Hematol; 2017 May; 96(5):847-858. PubMed ID: 28238095
[TBL] [Abstract][Full Text] [Related]
27. Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway.
Steiner H; Godoy-Tundidor S; Rogatsch H; Berger AP; Fuchs D; Comuzzi B; Bartsch G; Hobisch A; Culig Z
Am J Pathol; 2003 Feb; 162(2):655-63. PubMed ID: 12547723
[TBL] [Abstract][Full Text] [Related]
28. Phthalates promote prostate cancer cell proliferation through activation of ERK5 and p38.
Zhu M; Huang C; Ma X; Wu R; Zhu W; Li X; Liang Z; Deng F; Wu J; Geng S; Xie C; Zhong C
Environ Toxicol Pharmacol; 2018 Oct; 63():29-33. PubMed ID: 30125794
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of calcium-independent phospholipase A2 activates p38 MAPK signaling pathways during cytostasis in prostate cancer cells.
Sun B; Zhang X; Yonz C; Cummings BS
Biochem Pharmacol; 2010 Jun; 79(12):1727-35. PubMed ID: 20171194
[TBL] [Abstract][Full Text] [Related]
30. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
31. Prolonged extracellular signal-regulated kinase 1/2 activation during fibroblast growth factor 1- or heregulin beta1-induced antiestrogen-resistant growth of breast cancer cells is resistant to mitogen-activated protein/extracellular regulated kinase kinase inhibitors.
Thottassery JV; Sun Y; Westbrook L; Rentz SS; Manuvakhova M; Qu Z; Samuel S; Upshaw R; Cunningham A; Kern FG
Cancer Res; 2004 Jul; 64(13):4637-47. PubMed ID: 15231676
[TBL] [Abstract][Full Text] [Related]
32. The small GTPase ADP-Ribosylation Factor 1 mediates the sensitivity of triple negative breast cancer cells to EGFR tyrosine kinase inhibitors.
Haines E; Schlienger S; Claing A
Cancer Biol Ther; 2015; 16(10):1535-47. PubMed ID: 26176330
[TBL] [Abstract][Full Text] [Related]
33. Shikonin inhibits prostate cancer cells metastasis by reducing matrix metalloproteinase-2/-9 expression via AKT/mTOR and ROS/ERK1/2 pathways.
Chen Y; Zheng L; Liu J; Zhou Z; Cao X; Lv X; Chen F
Int Immunopharmacol; 2014 Aug; 21(2):447-55. PubMed ID: 24905636
[TBL] [Abstract][Full Text] [Related]
34. Epigallocatechin-3-gallate (EGCG) inhibits PC-3 prostate cancer cell proliferation via MEK-independent ERK1/2 activation.
Albrecht DS; Clubbs EA; Ferruzzi M; Bomser JA
Chem Biol Interact; 2008 Jan; 171(1):89-95. PubMed ID: 17931610
[TBL] [Abstract][Full Text] [Related]
35. Urokinase-induced smooth muscle cell responses require distinct signaling pathways: a role for the epidermal growth factor receptor.
Nicholl SM; Roztocil E; Davies MG
J Vasc Surg; 2005 Apr; 41(4):672-81. PubMed ID: 15874933
[TBL] [Abstract][Full Text] [Related]
36. Leptin stimulates ovarian cancer cell growth and inhibits apoptosis by increasing cyclin D1 and Mcl-1 expression via the activation of the MEK/ERK1/2 and PI3K/Akt signaling pathways.
Chen C; Chang YC; Lan MS; Breslin M
Int J Oncol; 2013 Mar; 42(3):1113-9. PubMed ID: 23354006
[TBL] [Abstract][Full Text] [Related]
37. Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells.
Bakin RE; Gioeli D; Sikes RA; Bissonette EA; Weber MJ
Cancer Res; 2003 Apr; 63(8):1981-9. PubMed ID: 12702592
[TBL] [Abstract][Full Text] [Related]
38. [Mechanism of the mitogen-activated protein kinase phosphatase-5 regulating the growth and invasion of a human prostate cancer cell line].
He HY; Fang WG; Zheng J; You JF; Heng WJ; Li Y
Zhonghua Yi Xue Za Zhi; 2003 Oct; 83(20):1812-7. PubMed ID: 14642090
[TBL] [Abstract][Full Text] [Related]
39. Overexpression of ARF1 is associated with cell proliferation and migration through PI3K signal pathway in ovarian cancer.
Gu G; Chen Y; Duan C; Zhou L; Chen C; Chen J; Cheng J; Shi N; Jin Y; Xi Q; Zhong J
Oncol Rep; 2017 Mar; 37(3):1511-1520. PubMed ID: 28098897
[TBL] [Abstract][Full Text] [Related]
40. Close correlation between MEK/ERK and Aurora-B signaling pathways in sustaining tumorigenic potential and radioresistance of gynecological cancer cell lines.
Marampon F; Gravina GL; Popov VM; Scarsella L; Festuccia C; La Verghetta ME; Parente S; Cerasani M; Bruera G; Ficorella C; Ricevuto E; Tombolini V; Di Cesare E; Zani BM
Int J Oncol; 2014 Jan; 44(1):285-94. PubMed ID: 24189697
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
